Rx-to-OTC switches
Many companies are interested in assessing the balance
of risks and benefits associated with conversion of prescription
drugs to over-the-counter status, or so-called "Rx-to-OTC switches".
PAI pioneered the development of techniques of risk-benefit analysis
in support of Rx-to-OTC switches, including nicotine replacement
products and H2-blockers. Studies of other "switch" candidates have
been completed or are underway.
|
|
|
